These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22797842)

  • 21. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of whole-body DW-MRI with 2-[
    Baratto L; Nyalakonda R; Theruvath AJ; Sarrami AH; Hawk KE; Rashidi A; Shen S; States L; Aboian M; Jeng M; Daldrup-Link HE
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1689-1698. PubMed ID: 36717409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine.
    Büchler T; Cervinek L; Belohlavek O; Kantorova I; Mechl M; Nebesky T; Vorlicek J; Adam Z
    Pediatr Blood Cancer; 2005 Mar; 44(3):286-8. PubMed ID: 15481071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Langerhans cell histiocytosis of the auditory canal detected by 18F-FDG PET/CT.
    Mueller RJ; Siegel A; Seltzer M; McKnight TA
    Clin Nucl Med; 2012 Sep; 37(9):908-9. PubMed ID: 22889788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coincidence FDG-PET in the evaluation of Langerhans' cell histiocytosis: preliminary findings.
    Binkovitz LA; Olshefski RS; Adler BH
    Pediatr Radiol; 2003 Sep; 33(9):598-602. PubMed ID: 12879314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective CT for PET/CT: dose reduction in Langerhans cell histiocytosis.
    Gelfand MJ; Sharp SE; Palumbo JS
    Pediatr Radiol; 2015 Jan; 45(1):81-5. PubMed ID: 25149158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder.
    Takehana CS; Twist CJ; Mosci C; Quon A; Mittra E; Iagaru A
    Nucl Med Commun; 2014 Mar; 35(3):276-81. PubMed ID: 24296883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ¹⁸F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas.
    Eugene T; Corradini N; Carlier T; Dupas B; Leux C; Bodet-Milin C
    Nucl Med Commun; 2012 Oct; 33(10):1089-95. PubMed ID: 22929116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging.
    Evangelista L; Panunzio A; Polverosi R; Ferretti A; Chondrogiannis S; Pomerri F; Rubello D; Muzzio PC
    Biomed Pharmacother; 2012 Sep; 66(6):448-53. PubMed ID: 22902054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
    Manohar K; Bhattacharya A; Mittal BR
    Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
    Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
    Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma.
    Szturz P; Řehák Z; Koukalová R; Adam Z; Krejčí M; Pour L; Zahradová L; Vaníček J; Nebeský T; Hájek R; Mayer J
    Nucl Med Biol; 2012 Apr; 39(3):429-36. PubMed ID: 22172385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
    Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.